The Effect of Curcumin on Inflammatory Markers in Hemodialysis Patients
ConditionHemodialysis
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-100
SponsorUniversity of Guadalajara
About this trial
The goal of this clinical trial is to learn if curcumin can lower the inflammation in participants with chronic kidney disease (CKD) undergoing hemodialysis (HD).
The main questions it aims to answer are:
Does curcumin lower can lower profinflamatory markers in participants with CKD on HD?
Researchers will compare curcumin to a placebo (a look-alike substance that contains no drug) to see if curcumin works to help the treatment in participants with CKD on HD.
Researchers will compare nutritional status and side effects after taking the supplement.
Participants will:
Take the curcumin or a placebo twice a day for 3 months Visit the clinic once every week for checkups and tests.
Eligibility criteria
Qualifiers
Patients of both sexes undergoing dialysis or hemodialysis.
Aged 18 years or older.
Clinically stable and receiving hemodialysis or dialysis for at least three months before study enrollment.
Continuation of pharmacotherapy as prescribed by their physician.
Disqualifiers
Active malignant disease (diagnosed within the past five years).
Critical illness requiring respiratory or circulatory support.
Severe congestive heart failure (NYHA class IV).
Severe chronic systemic infectious or inflammatory disease.
Trial design
Treatments tested in this trial
- Curcumin (Longvida™)
- Placebo
Treatment groups
70 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
University of Guadalajara
Lead sponsor
Hospital Civil de Guadalajara
Collaborator
Source ClinicalTrials.gov